Institut Mérieux Alliance – 78% stake in Shantha Biotechnics / Sanofi-Aventis

Exclusively advised Institut Mérieux in the divestiture of ShanH SAS, the 78% owned subsidiary of the French life-science Group Mérieux-Alliance holding a majority stake in the Indian Prophylactic Vaccine company Shantha Biotechnics to Sanofi-aventis, for a reference valuation of € 750m and a clinical milestone of € 50m after conducting a Global competitive auction and a local management presentation and due diligence process.